Showing results (1561-1570 of 1,885) with videos related to

Sort By:
Pageof 189
Early Human Development|April 17, 2026
Impact of catch-up growth on brain structures involved in emotional regulation in preterm children at 2 years of ageJ Uberos, F Contreras-Chova, C Santiago Boyero, et al.
Nature Medicine|August 17, 2023
Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trialAri VanderWalde, Shay L Bellasea, Kari L Kendra, et al.
The Journal of Allergy and Clinical Immunology|March 20, 2012
Genome-wide association study of lung function decline in adults with and without asthmaMedea Imboden, Emmanuelle Bouzigon, Ivan Curjuric, et al.
Stroke|January 26, 2026
2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke: A Guideline From the American Heart Association/American Stroke AssociationShyam Prabhakaran, Nestor R Gonzalez, Kori S Zachrison, et al.
Nature Cancer|January 29, 2026
Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trialKari L Kendra, Shay L Bellasea, Zeynep Eroglu, et al.
The New England Journal of Medicine|September 1, 2020
Cardiovascular and Renal Outcomes with Empagliflozin in Heart FailureMilton Packer, Stefan D Anker, Javed Butler, et al.
European Journal of Heart Failure|November 30, 2020
Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trialStefan D Anker, Javed Butler, Gerasimos Filippatos, et al.
The British Journal of Dermatology|May 7, 2021
A genome-wide association study identifies novel gene associations with facial skin wrinkling and mole count in Latin AmericansY Chen, M André, K Adhikari, et al.
Nature Medicine|August 14, 2025
Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trialKari L Kendra, Shay L Bellasea, Zeynep Eroglu, et al.
European Journal of Heart Failure|July 18, 2023
Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of HypertensionStefan D Anker, Muhammad Shariq Usman, Markus S Anker, et al.
Pageof 189